David Béchard
Gründer bei Cytune Pharma SAS
Profil
David Béchard is the founder.
He founded Endotis Pharma SARL in 2003, where he served as President & Chief Executive Officer from 2003 to 2012.
He also founded Cytune Pharma SAS in 2007 and currently holds the title of Chairman.
Dr. Béchard's former job includes being Vice President at Atlanpole Biotherapy.
In terms of education, Dr. Béchard is a graduate of École des Hautes Études Commerciales de Paris.
Aktive Positionen von David Béchard
| Unternehmen | Position | Beginn |
|---|---|---|
Cytune Pharma SAS
 Cytune Pharma SAS Miscellaneous Commercial ServicesCommercial Services Cytune Pharma SAS develops and manufactures immunotherapeutic agents for the treatment of cancer. It offers CYP 0150 produced by recombinant technology adapted to pharmaceutical processes and is the result of a single translation. The company was founded by David Béchard and Yannick Jacques on November 15, 2007 and is headquartered in Nantes, France. | Gründer | 15.11.2007 |
Ehemalige bekannte Positionen von David Béchard
| Unternehmen | Position | Ende |
|---|---|---|
| Atlanpole Biotherapy | Corporate Officer/Principal | - |
Endotis Pharma SARL
 Endotis Pharma SARL Pharmaceuticals: MajorHealth Technology Endotis Pharma SARL is a holding company, which is engaged in the development of differentiated cardiovascular therapeutics based on validated targets and modes of action. The company was founded in 2003 and it is headquartered in Romainville, France. | Gründer | - |
Ausbildung von David Béchard
| École des Hautes Études Commerciales de Paris | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Endotis Pharma SARL
Endotis Pharma SARL Pharmaceuticals: MajorHealth Technology Endotis Pharma SARL is a holding company, which is engaged in the development of differentiated cardiovascular therapeutics based on validated targets and modes of action. The company was founded in 2003 and it is headquartered in Romainville, France. | Health Technology |
Cytune Pharma SAS
Cytune Pharma SAS Miscellaneous Commercial ServicesCommercial Services Cytune Pharma SAS develops and manufactures immunotherapeutic agents for the treatment of cancer. It offers CYP 0150 produced by recombinant technology adapted to pharmaceutical processes and is the result of a single translation. The company was founded by David Béchard and Yannick Jacques on November 15, 2007 and is headquartered in Nantes, France. | Commercial Services |
| Atlanpole Biotherapy |
